Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results November 03, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options September 13, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces New Employee Inducement Grant August 15, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update August 04, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease August 01, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET July 28, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces New Employee Inducement Grant July 08, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET May 25, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease May 24, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 05, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET April 28, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022 April 26, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022 April 20, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET April 06, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer March 18, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update February 24, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer February 24, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET February 17, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer December 16, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions December 07, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences November 09, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update November 04, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021 October 28, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase October 21, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan October 12, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase October 07, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists October 06, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference September 27, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO September 21, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition September 20, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Tickers AERI Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.